Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 微芯生物是由资深留美归国博士团队于2001年3月创立的中国原创新药领域的先行者。公司秉承“原创、安全、优效、中国”的理念，专注对人类生命健康造成严重威胁的恶性肿瘤、代谢性疾病、自身免疫性疾病、中枢神经系统疾病及抗病毒五大领域的原创新药研发，致力于为患者提供可承受的、临床亟需的、具有革命性疗效的创新机制药物。微芯生物是科创板首家过会企业及第一家上市的生物医药企业（股票代码688321.SH）。
Main Business 恶性肿瘤、代谢性疾病、自身免疫性疾病、中枢神经系统疾病及抗病毒五大领域的原创新药研发
Legal Representative XIANPING LU
Top Executives
董事长：XIANPING LU
董事：李伟华,杨晗鹏,海鸥,黎建勋
独立董事：王艳梅,黄民,罗勇根
Top 5 Shareholder
Shareholder name Nature Holding Date
博奥生物集团有限公司流通A股8.51%30/09/2024
深圳市海粤门生物科技开发有限公司流通A股5.62%30/09/2024
XIANPING LU流通A股5.45%30/09/2024
深圳海德睿博投资有限公司流通A股4.86%30/09/2024
深圳市海德康成投资合伙企业（有限合伙）流通A股3.75%30/09/2024
Company Secretary 海鸥
Solicitors 上海市通力律师事务所
Auditors 毕马威华振会计师事务所（特殊普通合伙）
Tel No 0755-26952070
Fax No 0755-26957291
Website www.chipscreen.com
Email ir@chipscreen.com
Company Address
Register: 深圳市南山区沙河西路3157号南山智谷产业园B栋21F-24F
Office: 广东省深圳市南山区沙河西路3157号南山智谷产业园B栋21F-24F
Listing Date 12/08/2019
Shares Capital
Shares Capital: 407,795,845
Total A Share: 407,795,845
Listed A Share: 407,795,845
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.218
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 3.856
Market Capitalization(RMB) 10.166B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.